Karacabeyli D, Lacaille D, Lu N, McCormick N, et al. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study. PLoS One 2024;19:e0308533.
PMID: 39116084